Literature DB >> 20412037

Factors affecting compliance and persistence with treatment for hepatic encephalopathy.

Guy Neff1.   

Abstract

Noncompliance with treatment protocols produces an increased burden on the health care system. Reports show that 23% of annual admissions to nursing homes in the United States (380,000 patients) are due to noncompliance, resulting in overall costs of over $31 billion. More than 10% of all patients (3.5 million) are hospitalized each year due to complications related to noncompliance, with over $15 billion spent. In addition, nearly half of the 2 billion prescriptions filled each year are not taken correctly. Patients with cirrhosis and hepatic encephalopathy who are prescribed lactulose experience a greater frequency of adverse effects, require more hospitalizations, and suffer more disease recurrence than those prescribed rifaximin.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20412037     DOI: 10.1592/phco.30.pt2.22S

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  3 in total

1.  Targets to improve quality of care for patients with hepatic encephalopathy: data from a multi-centre cohort.

Authors:  Jasmohan S Bajaj; Jacqueline G O'Leary; Puneeta Tandon; Florence Wong; Patrick S Kamath; Scott W Biggins; Guadalupe Garcia-Tsao; Jennifer Lai; Michael B Fallon; Paul J Thuluvath; Hugo E Vargas; Benedict Maliakkal; Ram M Subramanian; Leroy R Thacker; K Rajender Reddy
Journal:  Aliment Pharmacol Ther       Date:  2019-04-29       Impact factor: 8.171

Review 2.  Safety, efficacy, and patient acceptability of rifaximin for hepatic encephalopathy.

Authors:  Nina Kimer; Aleksander Krag; Lise L Gluud
Journal:  Patient Prefer Adherence       Date:  2014-03-18       Impact factor: 2.711

3.  A retrospective study of drug utilization and hospital readmissions among Medicare patients with hepatic encephalopathy.

Authors:  Aisha Vadhariya; Hua Chen; Omar Serna; Hani Zamil; Susan M Abughosh
Journal:  Medicine (Baltimore)       Date:  2020-04       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.